Envista Holdings Corporation
NVST
$23.55
-0.51%
Envista Holdings Corporation is a global dental products company that develops, manufactures, and markets a portfolio of dental consumables, equipment, and services to dental professionals. It operates through two segments: Specialty Products & Technologies, which is the key revenue driver focused on dental implants, orthodontics, and associated software, and Equipment & Consumables. The company is a significant player in the dental equipment and supplies industry, having been spun off from Danaher, which lends it a legacy of operational discipline. The current investor narrative centers on a potential turnaround and margin recovery story, as recent quarterly results have shown a return to profitability and solid revenue growth, sparking debate on whether the company can sustain this momentum and improve its historically volatile earnings profile.…
NVST
Envista Holdings Corporation
$23.55
Investment Opinion: Should I buy NVST Today?
Rating: Hold. The core thesis is that NVST presents a compelling but unproven turnaround story where near-term technical weakness and valuation risk offset improving fundamentals, warranting a wait-and-see approach.
Supporting Evidence: The Hold rating is supported by four key data points. First, the forward P/E of 15.0x (based on $1.91 EPS) is reasonable and suggests limited upside if earnings materialize as expected. Second, while Q4 revenue grew 14.96% YoY, the stock's -19.38% 3-month return shows the market is skeptical of sustainability. Third, the company's strong free cash flow generation ($230.4M TTM) and solid balance sheet (D/E of 0.55) provide a margin of safety. Finally, analyst sentiment is lukewarm, with only 2 of 5 analysts rating it a Buy/Overweight, suggesting limited near-term catalysts for a re-rating.
Risks & Conditions: The two biggest risks are a failure to maintain quarterly profitability, invalidating the recovery, and a further compression in the forward P/E multiple if growth slows. This Hold would upgrade to a Buy if the stock stabilizes above key technical support (e.g., $20) while Q1 2026 results confirm the Q4 profit trend, or if the forward P/E compresses below 12x. It would downgrade to a Sell if revenue growth decelerates below 5% YoY or if the company reports another net loss. Relative to its own volatile history and given the mixed signals, the stock appears fairly valued at current levels, pricing in a successful but uncertain recovery.
Sign up to view all
NVST 12-Month Price Forecast
The AI assessment is Neutral with Medium confidence. The investment thesis is bifurcated: the fundamental story is improving, but the market's reaction has been sharply negative, creating a standoff. The stock is caught between its 52-week high of $30.42, representing the bull case of a full recovery, and its low of $17.78, representing a failed turnaround. The most likely path is a volatile range-bound trade (base case, 60% probability) as investors await conclusive evidence on earnings sustainability. The stance would upgrade to Bullish on a confirmed breakout above $30 on strong volume and consecutive profitable quarters. It would downgrade to Bearish on a breakdown below $20 accompanied by a quarterly loss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Envista Holdings Corporation's 12-month outlook, with a consensus price target around $30.62 and implied upside of +30.0% versus the current price.
Average Target
$30.62
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$19 - $31
Analyst target range
Analyst coverage for NVST is limited, with only 5 analysts providing estimates, indicating it is a mid-cap stock with moderate institutional interest. The consensus sentiment appears neutral to cautiously optimistic, with recent ratings including one 'Buy' (Stifel), one 'Overweight' (Barclays), and three 'Neutral' or 'Equal Weight' ratings (Mizuho, Wells Fargo, JP Morgan). The average EPS estimate for the coming period is $1.91, with a narrow range from $1.88 to $1.94, suggesting strong agreement on near-term earnings potential. The average revenue estimate is $3.17 billion. While specific price targets are not provided in the data, the limited number of analysts and the mix of ratings point to a consensus that is not decisively bullish. The lack of a defined target price range and the neutral stance from several major firms signal uncertainty about the stock's near-term catalysts and the sustainability of its recent fundamental improvement. This limited coverage can contribute to higher volatility and less efficient price discovery compared to more widely followed names.
Bulls vs Bears: NVST Investment Factors
The bull case, anchored by a strong Q4 revenue rebound (14.96% YoY), robust free cash flow ($230.4M TTM), and a reasonable forward P/E of 15.0x, argues for a successful margin recovery and turnaround. The bear case, however, is supported by severe recent price weakness (-19.38% over 3 months), volatile profitability (Q3 loss to Q4 profit), and a sky-high trailing P/E of 77.6x that prices in near-perfect execution. Currently, the bearish technical momentum and valuation concerns hold stronger evidence, as the stock's breakdown contradicts the improving fundamentals. The single most important tension in the investment debate is whether the company's return to profitability in Q4 2025 marks the beginning of a sustainable earnings recovery that justifies its elevated trailing valuation, or if it is merely a temporary respite in a longer-term story of volatile margins and disappointing execution.
Bullish
- Strong Revenue Growth Trajectory: Q4 2025 revenue grew 14.96% YoY to $750.6M, marking sequential quarterly growth from $616.9M in Q1. This indicates strengthening demand across the dental portfolio, particularly in the key Specialty Products segment, which generates $1.21B annually.
- Robust Free Cash Flow Generation: The company generated $91.7M in free cash flow in Q4 2025 and $230.4M TTM. This strong cash generation, coupled with a solid current ratio of 2.38, provides financial flexibility for investments, debt reduction, or shareholder returns.
- Attractive Forward Valuation: The forward P/E of 15.0x, based on consensus EPS of $1.91, is reasonable for a healthcare company showing a recovery. This is a stark discount to the trailing P/E of 77.6x, reflecting expectations for normalized profitability.
- Solid Gross Margin Profile: The company maintains a healthy gross margin of 55.04%, consistent with its TTM gross margin of 55.02%. This indicates pricing power and cost control in its core manufacturing operations, providing a foundation for operating margin expansion.
Bearish
- Severe Near-Term Price Weakness: The stock is down 9.07% over the past month and 19.38% over three months, underperforming the SPY by -15.38% and -29.66%, respectively. This breakdown in momentum and loss of relative strength signals waning investor confidence in the recovery story.
- Volatile and Thin Operating Margins: Despite solid gross margins, operating margins remain thin at 8.30%. The Q3 2025 net loss of $30.3M highlights ongoing earnings volatility, raising questions about the sustainability of the Q4 profit recovery.
- Elevated Trailing P/E and High Short Interest: A trailing P/E of 77.6x is extremely high and indicates the stock is priced for perfection. A short ratio of 3.53 reflects significant bearish sentiment and skepticism about the company's ability to meet elevated earnings expectations.
- Limited Analyst Conviction: Only 5 analysts cover the stock, with a mix of one Buy, one Overweight, and three Neutral ratings. This limited and non-consensus coverage suggests institutional uncertainty and can lead to higher volatility and less efficient price discovery.
NVST Technical Analysis
The stock is in a volatile recovery phase within a broader downtrend from its recent highs. Over the past year, the stock has gained 27.57%, but this masks significant volatility; it is currently trading at $23.55, which is approximately 77% of its 52-week high of $30.42 and 132% above its 52-week low of $17.78. This positioning near the middle of its annual range suggests the stock is consolidating after a sharp rally and subsequent pullback, indicating a balance between recovery optimism and lingering skepticism. Recent momentum has turned sharply negative, with the stock down 9.07% over the past month and down 19.38% over the past three months, significantly underperforming the SPY, which gained 6.31% and 10.28% over the same periods, respectively. This pronounced negative relative strength of -15.38% over one month signals a breakdown in near-term momentum and a loss of investor confidence, diverging from the positive longer-term trend. Key technical support is at the 52-week low of $17.78, while resistance sits at the recent high of $30.42. A sustained break below the $23 level could target the $20 support zone, while a move above $30 would signal a resumption of the uptrend. With a beta of 0.925, the stock exhibits slightly less volatility than the broader market, but the recent price action and a short ratio of 3.53 indicate elevated bearish sentiment and potential for sharp moves.
Beta
0.93
0.93x market volatility
Max Drawdown
-23.8%
Largest decline past year
52-Week Range
$18-$30
Price range past year
Annual Return
+27.6%
Cumulative gain past year
| Period | NVST Return | S&P 500 |
|---|---|---|
| 1m | -9.1% | +5.0% |
| 3m | -19.4% | +10.2% |
| 6m | +12.7% | +11.0% |
| 1y | +27.6% | +28.4% |
| ytd | +8.6% | +10.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NVST Fundamental Analysis
Revenue growth has shown a positive trajectory, with the most recent Q4 2025 quarterly revenue reaching $750.6 million, representing a 14.96% year-over-year increase. This follows a pattern of sequential quarterly revenue growth from $616.9M in Q1 to $750.6M in Q4, indicating a strengthening demand environment. The growth is driven by both segments, with Specialty Products and Technologies generating $1.21 billion and Equipment and Consumables contributing $679.3 million annually, highlighting the company's diversified portfolio. Profitability has been inconsistent but showed a marked improvement in the latest quarter. Q4 2025 net income was $32.9 million, a sharp recovery from a net loss of $30.3 million in Q3 2025. The gross margin for Q4 was a healthy 55.04%, consistent with the trailing gross margin of 55.02%, but operating margins remain thin at 8.30% (based on the operating margin ratio), indicating ongoing cost pressures. The company's balance sheet and cash flow generation are relative strengths. It maintains a robust current ratio of 2.38 and a moderate debt-to-equity ratio of 0.55. More importantly, the company generated $108 million in operating cash flow and $91.7 million in free cash flow in Q4 2025, contributing to a trailing twelve-month free cash flow of $230.4 million. This strong cash generation, coupled with an ROE of 1.51% and ROA of 3.01%, suggests the company is financially stable and capable of funding its operations internally.
Quarterly Revenue
$750600000.0B
2025-12
Revenue YoY Growth
+0.14%
YoY Comparison
Gross Margin
+0.55%
Latest Quarter
Free Cash Flow
$230400000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NVST Overvalued?
Given the company's positive but modest net income, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The trailing P/E is elevated at 77.6x, heavily influenced by periods of low or negative earnings, while the forward P/E is a more reasonable 15.0x, indicating the market expects a significant earnings recovery. The large gap between trailing and forward multiples reflects expectations for normalized profitability following recent quarterly improvements. Compared to sector averages, the stock's forward P/E of 15.0x appears reasonable, though direct industry comps are not provided in the data. The Price-to-Sales ratio of 1.34x and EV/Sales of 1.55x suggest the market is valuing the company at a moderate multiple of its revenue base. Historically, the stock's own valuation has been volatile. The current trailing P/E of 77.6x is near the top of its recent historical range, which has seen figures from negative to over 690x during periods of minimal earnings. The current Price-to-Book of 1.17x is consistent with its historical range around 1.0x-1.3x over the past several quarters. Trading near the high end of its own historical P/E band suggests the market has already priced in a substantial earnings recovery, leaving little room for error.
PE
77.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -28x~693x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is earnings volatility, as evidenced by the swing from a $30.3M net loss in Q3 2025 to a $32.9M profit in Q4. While free cash flow is strong ($230.4M TTM), operating margins are thin at 8.30%, indicating the company remains susceptible to cost pressures that could quickly erase profitability. Furthermore, the trailing P/E of 77.6x implies the market expects flawless execution; any deceleration from the recent 14.96% revenue growth rate could trigger a severe multiple contraction.
Market & Competitive Risks: The stock's high trailing P/E of 77.6x, near the top of its own historical range, presents significant valuation compression risk if growth moderates. With a beta of 0.925, it exhibits slightly less volatility than the market, but its recent -19.38% 3-month drop amid a rising market (SPY +10.28%) indicates significant company-specific or sector-specific headwinds. The elevated short interest (ratio of 3.53) signals a crowded bearish bet that could exacerbate selling pressure on any negative news, creating a feedback loop of underperformance.
Worst-Case Scenario: The worst-case scenario involves a failure to sustain the Q4 profit recovery, leading to a return to quarterly losses. This would shatter the turnaround narrative, causing analyst downgrades from their currently neutral stance and a rapid de-rating from the lofty trailing P/E. Combined with high short interest fueling a sell-off, the stock could re-test its 52-week low of $17.78. From the current price of $23.55, this represents a realistic downside of approximately -24.5%.
FAQ
The key risks are, in order of severity: 1) Earnings Volatility Risk: The company swung from a $30.3M loss in Q3 2025 to a $32.9M profit in Q4; a return to losses would crush the thesis. 2) Valuation Compression Risk: The lofty trailing P/E of 77.6x leaves no room for error; any earnings disappointment could cause a severe multiple contraction. 3) Sentiment & Technical Risk: High short interest (3.53) and severe recent underperformance (-19.38% over 3 months) indicate negative momentum that could persist. 4) Execution Risk: Thin operating margins of 8.30% must expand to justify the investment, which is not guaranteed in a competitive dental market.
The 12-month forecast for NVST is a range-bound outcome with a skew to the upside if execution improves. The base case (60% probability) sees the stock trading between $22 and $27 as the company delivers on consensus EPS of $1.91 but struggles to re-rate higher. The bull case (25% probability) targets $30 to $34 on sustained profitability and margin expansion. The bear case (15% probability) could see a retest of the 52-week low near $17.78 if the recovery stalls. The most likely scenario is the base case, predicated on the assumption that revenue growth moderates but remains positive while profitability stabilizes.
NVST's valuation presents a paradox. Based on trailing earnings, it appears extremely overvalued with a P/E of 77.6x. However, based on forward earnings expectations ($1.91 EPS), it looks reasonably valued with a forward P/E of 15.0x. This large gap shows the market is pricing in a significant earnings recovery. Compared to its own volatile history, the stock is trading near the high end of its P/E range. The Price-to-Sales ratio of 1.34x is moderate. Overall, the stock is fairly valued for the recovery it is expected to deliver, but it is overvalued if that recovery falters.
NVST is a high-risk, high-potential-reward stock that may be a good buy only for specific investors. The forward P/E of 15.0x and strong free cash flow ($230.4M TTM) suggest value if the earnings recovery holds. However, the severe recent underperformance (-19.38% over 3 months), elevated short interest (3.53), and volatile earnings history make it a speculative bet. It could be a good buy for a patient, contrarian investor with a multi-year horizon who believes in the margin recovery story, but it is not suitable for risk-averse or short-term investors given the clear lack of near-term momentum.
NVST is unsuitable for short-term trading due to its high volatility, negative recent momentum (-9.07% over 1 month), and lack of near-term catalysts, as evidenced by mixed analyst ratings. It is a long-term, speculative turnaround story. Investors should have a minimum holding period of 2-3 years to allow the company to demonstrate sustained quarterly profitability and margin improvement. The absence of a dividend further supports a growth-oriented, long-term holding strategy. The stock's beta of 0.925 suggests it is slightly less volatile than the market, but its company-specific risks dominate its profile.